In a laboratory study published in 2025, proanthocyanidins (PACs) were isolated from the specialized ginkgo extract EGb 761® and evaluated using in vitro and in vivo assays in combination with LC-MS1-metabolite profiling to assess their pharmacological activity, oral bioavailability, and metabolism. The results support the hypothesis that, in addition to flavonol glycosides and terpene lactones, PACs also actively contribute to the therapeutic effects of EGb 761®.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D
SGLT2i, metformin, or both?
- Biophilic Design of Work Environments
Effects on Health, Well-Being, and Productivity
- From symptom to diagnosis
Intrapelvic mass with an ambiguous differential diagnosis
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack
Comprehensive diagnostic testing can reduce the risk of stroke
- Malignant Tumors of the Clavicle
Surgical Challenges and Recurrence Patterns
- Chronic hand eczema: common, long-lasting, and distressing